Abstract Number: 186 • 2020 Pediatric Rheumatology Symposium
Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases
Background/Purpose: Chronic rheumatic diseases in children and adolescents increase cardiovascular risk. Thus, knowing the eating habits, biomarkers of lipid metabolism and the lifestyle of patients…Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium
The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus
Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium
The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort
Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…Abstract Number: 052 • 2020 Pediatric Rheumatology Symposium
Nasopharyngeal Pneumococcus Colonization in Patients with Childhood Onset Systemic Lupus Erythematosus (cSLE) Compared to Healthy Controls
Background/Purpose: Streptococcus pneumoniae (S. pneumoniae) may lead to severe life-threatening infections in both the general and immunocompromised population. Patients diagnosed with Systemic Lupus Erythematosus (SLE)…Abstract Number: 056 • 2020 Pediatric Rheumatology Symposium
Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series
Background/Purpose: Non-criteria antiphospholipid antibodies (NC-aPL) bind molecules such as phosphatidylethanolamine (PE), phosphatidylserine (PS), and prothrombin (Pt), but not the targets of routine antiphospholipid (aPL) testing…Abstract Number: 075 • 2020 Pediatric Rheumatology Symposium
Pseudotumor Cerebri Syndrome in Children with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that typically affects multiple organs and can lead to potentially fatal complications. Management of…Abstract Number: 083 • 2020 Pediatric Rheumatology Symposium
Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Background/Purpose: Transition of pediatric lupus (pSLE) patients from pediatric to adult rheumatology care is historically difficult and challenging. We aim to investigate disease activity and…Abstract Number: 094 • 2020 Pediatric Rheumatology Symposium
A Good Inter- and Intra-observer Reliability of Subtypes in Nailfold Capillary Micro-haemorrhages in Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: In previous studies, micro-haemorrhages have often been observed in nailfold capillaroscopy in SLE.1 The interpretation of this finding is still a topic of research.…Abstract Number: L15 • 2019 ACR/ARP Annual Meeting
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…Abstract Number: L18 • 2019 ACR/ARP Annual Meeting
A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study
Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…Abstract Number: 83 • 2019 ACR/ARP Annual Meeting
Dysfunction of TRIM21 Promotes Aberrant Plasmablast Differentiation in Systemic Lupus Erythematosus Due to the Reduction of TRIM21-mediated Ubiquitylation of IRF5
Background/Purpose: TRIM21 is a member of the tripartite motif family proteins and is one of the autoantigens which react with anti-SS-A antibody (Ab) present in…Abstract Number: 659 • 2019 ACR/ARP Annual Meeting
Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity
Background/Purpose: B-cells play a pivotal role in the initiation and perpetuation of systemic lupus erythematosus (SLE). Recently, it has been demonstrated that in active SLE…Abstract Number: 862 • 2019 ACR/ARP Annual Meeting
First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study
Background/Purpose: Aberrantly activated T- and B-lymphocytes play a major pathophysiological role in SLE. Cenerimod, a potent, selective sphingosine-1-phosphate 1 receptor modulator, blocks the egress of…Abstract Number: 1035 • 2019 ACR/ARP Annual Meeting
Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects females (9:1) over males. Despite significant research effort, the exact mechanisms behind this compelling sex bias are undefined.…
- « Previous Page
- 1
- …
- 128
- 129
- 130
- 131
- 132
- …
- 150
- Next Page »